Valuation: SCYNEXIS, Inc.

Market Cap 48.16M 41.49M 39.29M 35.61M 66.81M 4.6B 67.14M 467M 179M 2.34B 181M 177M 7.4B P/E 2026 *
-1.66x
P/E 2027 * -2.09x
Enterprise Value 48.16M 41.49M 39.29M 35.61M 66.81M 4.6B 67.14M 467M 179M 2.34B 181M 177M 7.4B EV / Sales 2026 *
77.7x
EV / Sales 2027 * 7.21x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+2.98%
1 week-8.68%
Current month-7.46%
1 month-5.47%
3 months+14.42%
6 months-29.55%
Current year-4.33%
1 week 4.63
Extreme 4.63
5.35
1 month 4.63
Extreme 4.63
6.09
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
9.52
3 years 3.53
Extreme 3.53
29.28
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 50 09/09/2026
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Free

Chief Financial Officer

100,000 1.0051%
4/1/26 A Buy

Chief Executive Officer

217,390 0.2736%
1/29/26 A Free

Chief Financial Officer

129,833 0.3094%
Change 5-day change 1-year change 3-year change Capi.($)
+2.98%-8.68%-45.98%-82.10% 48.16M
-0.65%-2.93%+47.70%+86.30% 994B
-0.29%-3.51%+49.15%+61.95% 640B
+0.83%+0.26%+17.76%+70.10% 454B
+4.95%+1.84%+38.29%+38.74% 337B
+2.78%-8.27%+17.84%+26.14% 261B
+3.05%+0.02%+5.52%+11.37% 246B
-1.34%-13.70%+36.53%+46.70% 204B
+2.16%-5.52%-20.46%-58.64% 190B
-0.75%-4.82%+25.46%+85.90% 178B
Average +1.64%-6.05%+17.18%+28.65% 350.48B
Weighted average by Cap. +1.46%-4.42%+32.52%+55.27%

Financials

2026 *2027 *
Net sales 620K 534K 505K 458K 859K 59.18M 864K 6M 2.31M 30.11M 2.33M 2.28M 95.15M 6.68M 5.75M 5.45M 4.94M 9.26M 638M 9.31M 64.7M 24.88M 325M 25.08M 24.53M 1.03B
Net income -30.55M -26.32M -24.92M -22.59M -42.38M -2.92B -42.6M -296M -114M -1.48B -115M -112M -4.69B -32.43M -27.94M -26.46M -23.98M -44.99M -3.1B -45.22M -314M -121M -1.58B -122M -119M -4.98B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
11/09/26 $4.840 +2.98% 30,448
10/09/26 $4.700 -4.28% 47,344
09/09/26 $4.910 -4.66% 58,565
08/09/26 $5.150 -2.83% 33,070
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.840USD
Average target price
36.55USD
Spread / Average Target
+655.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!